Akèy › Kansè poumon › North Carolina › Durham
Etid klinik pou Kansè poumon nan Durham, NC
32 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Durham VA Medical Center, Durham
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- Duke Cancer Center, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi lwen
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Durham
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- Duke University Medical Center, Durham
Study of Trilaciclib and Lurbinectidin
Ap rekriteFaz 2
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill · 10 mi lwen
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Ap rekriteFaz 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mi lwen
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Duke University School of Medicine, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
Ap rekriteFaz 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 10 mi lwen
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Health Education Approach to Lung Screening
Ap rekriteVolontè an sante akeyi
- University of North Carolina-Chapel Hill, Carrboro · 11 mi lwen
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Ap rekriteFaz 1
- Xencor Investigative Site, Durham
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Ap rekriteFaz 1/2
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Ap rekrite
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi lwen
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Duke Cancer Center, Durham
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Durham VA Medical Center, Durham
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
Ap rekriteVolontè an sante akeyi
- Duke University, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Ap rekrite
- Durham VA Medical Center, Durham, NC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Duke Cancer Institute, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
Ap rekriteFaz 1 bonè
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi lwen
UNC Pleural Fluid Registry
Ap rekriteEtid obsèvasyon
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Durham
- Kansè nan tete63 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Kansè Metastatik33 etid
- Leksemi mieloïd egi33 etid
- Kansè pwostat32 etid
- Kansè kolorektal28 etid
- Lukemi lenfositè kwonik27 etid
- Kansè ovè27 etid
- Ensifizyans kadyak26 etid
- Kansè pankreyas24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.